37 results about "Myelitis" patented technology

A method is provided for treating a subject, including applying a current to a site of the subject selected from the list consisting of: a vagus nerve of the subject, an epicardial fat pad of the subject, a pulmonary vein of the subject, a carotid artery of the subject, a carotid sinus of the subject, a vena cava vein of the subject, and an internal jugular vein of the subject. The method also includes configuring the current so as to treat a condition of the subject selected from the list consisting of: an autoimmune disease, an autoimmune inflammatory disease, multiple sclerosis, encephalitis, myelitis, immune-mediated neuropathy, myositis, dermatomyositis, polymyositis, inclusion body myositis, inflammatory demyelinating polyradiculoneuropathy, Guillain Barre syndrome, myasthenia gravis, inflammation of the nervous system, inflammatory bowel disease, Crohn's disease, ulcerative colitis, SLE (systemic lupus erythematosus), rheumatoid arthritis, vasculitis, polyarteritis nodosa, Sjogren syndrome, mixed connective tissue disease, glomerulonephritis, thyroid autoimmune disease, sepsis, meningitis, a bacterial infection, a viral infection, a fungal infection, sarcoidosis, hepatitis, and portal vein hypertension.

The invention belongs to the field of medical health products, and in particular relates to a pharmaceutical composition for promoting nerve injury restoration and an application thereof. The pharmaceutical composition in each unit contains 0.5-8g of L-ornithine, 1-5g of aspartic acid, 3-10g of arginine, 3-10g of vitamin B6, and the balance of accessories and / or other components. The pharmaceutical composition disclosed by the invention can obviously promote the restoration of spinal nerve function, and can be used for preparing medicines of nerve injury restoration; and the pharmaceutical composition has very good curative effect on avute myelitis.

A pharmaceutical composition for promoting nerve injury restoration and a use thereof are disclosed. Each unit of the pharmaceutical composition contains 0.5 to 8 g of L-ornithine, 1 to 5 g of aspartic acid, 3 to 10 g of arginine and 3 to 10 g of vitamin B6. The pharmaceutical composition can significantly promote recovery of the spinal nerve function, and particularly has a good therapeutic effect on acute myelitis.

2-Chloro-2′-deoxyadenosine, hereinafter referred to as cladribine, or a pharmaceutically acceptable salt thereof may be used in the treatment or amelioration of neuromyelitis optica, hereinafter referred to as NMO e.g. in patients known to have NMO-IgG seropositivity or in patients optic neuritis, myelitis and at least two of MRI evidence of contiguous spinal cord lesion 3 or more segments in length, onset brain MRI nondiagnostic for multiple sclerosis or NMO-IgG seropositivity.

The invention provides an indomethacin cataplasm, which is composed of a backing, a paste body, and an anti-sticking film, wherein the paste body is composed of indomethacin, crotamiton, N-methyl pyrrolidone, and hydrogel matrix; the content of the indomethacin in the paste body is 0.1 to 3 wt%, the weight of crotamiton is 0.1 to 6 times as heavy as that of indomethacin, the weight of N-methyl pyrrolidone is 1 to 15 times as heavy as that of indomethacin, and the balance being hydrogel matrix. The mixed solvent of crotamiton and N-methyl pyrrolidone can increase the solubility of indomethacin so as to completely dissolve indomethacin, the indomethacin is evenly dispersed in hydrogel matrix and will not crystallize for a long time, moreover the skin penetrating performance of indomethacin is improved, and indomethacin can be more easily absorbed by the skin. Furthermore, a skin penetration promoter and a wetting agent are added to ensure that the cataplasm has a high water content and remains wet for a long time, and the skin penetration and absorption of the drugs are also promoted. The provided indomethacin cataplasm can be used to treat arthralgia diseases such as rheumatic arthritis, gouty arthritis, rigidity myelitis, tenosynovitis, and the like.

The invention provides application of magnolol to preparation of a drug for preventing and / or treating myelitis. The magnolol can significantly reduce inflammatory cell infiltration in EAE model mouse spinal cord, and also significantly alleviates demyelination phenomenon. Therefore, the magnolol can be used for preparing the drug for preventing or treating autoimmune encephalomyelitis. The invention provides a novel therapeutic drug for clinical treatment of autoimmune encephalomyelitis.

The present invention is related to a method, system or process for screening, studying and treating disorders which have a component of mercurial including: autism, autism spectrum disorders, ADD, ADHD, mental retardation, Asperger's syndrome, childhood psychoses, stammering, stuttering, tics, repetitive movements, eating disorders, sleep disorders, enuresis, disturbances of emotion, developmental language disorders, developmental speech disorders, developmental delay, Alzheimer's disease, diabetes, heart disease, obesity, ALS, nephritic syndrome, renal failure, asthma, systemic lupus, autoimmune thyroiditis, rheumatoid arthritis, arthritis, vasculitis, myelitis, glomerulonephritis, optic neuritis, infantile cerebral palsy, epilepsy, migraine, toxic encephalopathy, polyneuropathy, cerebral degenerations, anterior horn cell disease, spinocerebellar disease, extrapyramidal disease, and myopathy, and other related disorders. The invention of a method of screening, studying and treating of these disorders by utilizing the interaction of mercurial with the steroidgenesis pathway and its control by the hypothalamus-pituitary-adrenal axis is described.

The invention discloses application of chrysin in preparation of medicaments for treating autoimmune diseases. Experimental results show that the chrysin can inhibit differentiation of human immune dendritic cells (DC) and maturity of LPS (lipopolysaccharide)-activated human immune DC, can inhibit the antigen uptake capabilities of the immature DC and the antigen presenting capabilities of the mature DC and can inhibit T cell proliferation reactions stimulated by the DC. In particular, the chrysin can reduce the average score, the highest score and the total score of clinical scores of experimental autoimmune encephalomyelitis of mice and can relieve myelitis cell infiltration and demyelination in spinal cords. Thus, the medicament inhibiting immune systems is expected to become the medicament for treating such autoimmune inflammatory diseases as multiple sclerosis, neuromyelitis optica and acute disseminated encephalomyelitis clinically.

The invention discloses a traditional Chinese medicine composition. The composition is prepared from, by weight, 200-205 parts of radix rehmanniae preparata, 130-140 parts of Chinese pyrola herbs, 130-140 parts of rhzizoma drynariae, 130-140 parts of suberect spatholobus stem, 130-140 parts of cistanche deserticola, 130-140 parts of epimedium herbs and 80-90 parts of fried radish seeds. The invention further discloses a preparation method and application of the traditional Chinese medicine composition. The composition has the functions of tonifying the kidney, activating blood, diminishing inflammation and relieving the pain. The traditional Chinese medicine composition is used for hypertrophic myelitis, cervical spondylosis, calcaneal spur, proliferative arthritis and Kashin-Beck diseases. The composition further has the functions of improving mesentery circulation and promoting functional repairing of the stomach and intestines and is applied to treatment of stomach and intestine injuries and the like.

The invention relates to a new preparation of a yam pill and a method for controlling the quality of the preparation. The aim of the invention is to provide a preparation method that: 45g of yam, 21g of eucommia bark (carbonizing by stir-frying), 30g of achyranthes, 105g of liquorice, 9g of aucklandia root, 12g of frankincense (vinegar prepared), 12g of myrrh (vinegar prepared), 9g of homalomena rhizome, 30g of pyritum (vinegar calcined and quenched), 9g of notopterygium root, 9g of anisetree bark, 9g of safflower, 9g of ledebouriella seseloides, 21g of radix dipsaci, 12g of radix bupleuri, 30g of rhizoma cibotii (sand scalded), 60g of Chinese ephedra, 120g of nux vomica powder and pharmaceutically acceptable accessories undergoes the necessary procedure of pulverization, uniform mixing, pellet fabrication, pill fabrication, encapsulation, tablet pressing, etc., and then prepared into pharmaceutically acceptable preparation, such as common tablets, capsules, soft capsules, watered pills, watered-honeyed pills, small honeyed pills, etc. In addition, the aim of the invention is to provide the method for controlling the quality of the preparation, and the new therapeutic applications in the aspects of cervical spondylosis, prolapse of lumbar intervertebral disc, rheumatism, rheumatoid diseases, synovitis, femoral head necrosis, acute myelitis, progressive myatrophy, myasthenia gravis and periodic paralysis.

The invention discloses a neural interventional treatment postoperative nursing device. A barrier is arranged on the outer side of a nursing bedstead of the neural interventional treatment postoperative nursing device, a slide groove is formed in the rear side of the nursing bedstead, an infusion support is arranged on the upper side of the slide groove, an infusion bottle is hung on the infusionsupport and is fixedly connected with a transition cushion bottle by a delivery tube, a ladder is arranged on the rear side of the slide groove, brackets are arranged on the lower sides of four bottomcorners of the nursing bedstead, locking wheels are arranged on the lower sides of the brackets, fixing buckles are arranged on the locking wheels, a support plate is arranged at the right end of thenursing bedstead, and an oxygen supply machine is arranged on the upper side of the support plate. The neural interventional treatment postoperative nursing device has the advantages that the neuralinterventional treatment postoperative nursing device is provided with the oxygen supply machine, an artificial respirator and a pulse monitoring instrument, accordingly, patients who suffer from clinical common internal medicine diseases such as paralysis agitans neurological diseases, myasthenia gravis (MG) diseases, Guillain-Barre syndrome (GBS) diseases and acute myelitis can be timely nursedand treated by the aid of the neural interventional treatment postoperative nursing device, rehabilitation of the patients can be effectively promoted, and good nursing effects can be realized by theneural interventional treatment postoperative nursing device.

The invention discloses an iliacus muscle oral liquid and a preparation method thereof. The iliacus muscle oral liquid comprises the components of, by weight, 27 parts of frankincense, 46 parts of myrrh, 91 parts of white peony root, 27 parts of rhizoma corydalis (processed with vinegar), 46 parts of pseudo-ginseng, 27 parts of radix aucklandiae, 46 parts of safflower carthamus, 91 parts of radix curcumae, 183 parts of radix angelicae pubescentis, 46 parts of radix achyranthis bidentatae, 183 parts of large-leaved gentian, 46 parts of cassia twig, 27 parts of resina draconis and 27 parts of semen strychni (fried). The iliacus muscle oral liquid is a pure traditional Chinese medicine composition oral liquid preparation and has the functions for hypertrophic myelitis, cervical spondylosis, heel spurs, hypertrophic arthritis, kashin-beck diseases, etc. Compared with iliacus muscle pills, iliacus muscle tablets, iliacus muscle capsules which are described in Chinese medicine ministerial standards, the iliacus muscle oral liquid has the advantages of small dosage, good taste, convenience for taking, relatively fast absorption, high bioavailability, stable quality, simple production process, etc.

The invention discloses specific full nutrition formula food for a myelitis patient. The formula is developed according to requirements of General Rules of Food for Special Medical Purpose, by combining physical characters of the myelitis patient, and integrating with research results of advanced physiology, medicines, nutriology and clinical applications and the like of the Harvard University inAmerica at present, and on the basis of a quintessence theory (using homology of a liver, a spleen and a kidney as a main principle) of a traditional Chinese medicine of 'eliminating medium and nourishing' and 'balancing and maintaining'. The product is prepared by using multiple traditional Chinese medicine extract essences with medical and edible dual purposes, multiple probiotics, and an oligopeptide as principal raw materials, and using prebiotics, a carbohydrate, amino acid, multiple vitamins and mineral substances as accessories and mixing. In addition, the invention further provides a preparation method of the specific full nutrition formula food for the myelitis patient. The specific full nutrition formula food can be used as a single nutrition source for meeting nutrition requirements of the myelitis patient, and has the efficacy of benefiting Qi for activating blood circulation, warming Yang and clearing damp, dredging collaterals and tonifying kidney, strengthening tendons and bones, clearing heat and moistening lung, and nourishing Yin and promoting secretion of saliva.

The present invention relates to a pharmaceutical composition having efficacy in the treatment of inflammation, pain, arthritis and spinitis, and the proliferation and activity of ost eoblastic cells, and a preparation method thereof. The present invention provides a pharmaceutical composition comprising pharmaceutically effective components extracted from Cibotii Rhizoma, Ledebouriellae Radix, Achyranthes bidentatae Radix, Acanthopanacis Cortex, Eucommiae Cortex, and Glycine Semen nigra, and a preparation method thereof. The pharmaceutically effective components may be extracted using hot water, an organic solvent, or a mixed solvent thereof. Alternatively, the pharmaceutically effective components may be prepared by a UF membrane to have a molecular weight of not greater than 10,000.

The invention discloses a medicament for treating rheumathritis, hyperosteogeny and myelitis, which is prepared from Chinese angelica root, wood louse, dragon's blood resin, aspongopus, pangolin scales, Clematis chinensis, Japanese yam, psoralea fruit, eucommia bark, dried rehmannia root and Dendrobium nobile by a predetermined weight proportions. The medicament can be prepared into any of the conventional oral administration dosage forms.

The invention relates to a pharmaceutical composition for treating myelitis and a preparation method thereof, which is characterized in that it is made of the following raw materials in parts by weight: 6-9 parts of Scutellaria baicalensis, 6-9 parts of Pueraria lobata, 6-9 parts of Qingdai, and Mori Bai 6-9 parts of skin, 6-9 parts of Cangzhu, 4-6 parts of ghost needle grass, 6-9 parts of Shouwu vine, 6-9 parts of Shenjincao, 2-4 parts of Panax notoginseng, 6-9 parts of Daxueteng , 2-4 parts of maple gum, 4-6 parts of clove, 6-9 parts of Achyranthes bidentata, 6-9 parts of psoralen, 2-4 parts of Anemarrhena, 6-9 parts of Smilax, 6-9 parts of licorice. The beneficial effect of the invention is that: by extracting the active ingredients of the traditional Chinese medicine, the functions of sensory and motor nerves are restored, and the effects of clearing away heat and eliminating plague, promoting blood circulation and promoting qi, expelling wind and dampness, relieving spasm and relieving pain are achieved.

The invention belongs to the field of traditional Chinese medicine preparations, and aims to provide a traditional Chinese medicine composition for treating hypertrophic spondylitis and cervical spondylosis according to the understanding mechanism of traditional Chinese medicine on hypertrophic spondylitis and cervical spondylosis. Its mass ratio is as follows: Rehmannia glutinosa 30-320g, Luniancao 150-320g, Rhizoma drynariae (hot) 150-260g, Radix Paeoniae Alba 100-200g, Caulis Spatholobus 150-260g, Salvia miltiorrhiza 80-160g, Cistanche 100- 160g, 50-120g of safflower, 50-160g of epimedium, 80-160g of radish (fried), 50-120g of Gentiana, and an appropriate amount of honey; the medicine provided by the invention is a traditional Chinese medicine prescription for treating both symptoms and root causes.

The present invention discloses new application of neoarsphenamine. Said neoarsphenamine has the specific effect for curing the following 13 diseases: 1. rheumatoid arthritis; 2. various neuralgias of sciatica and intercostal neurolgia, etc. 3 angiitis; 4. leukemia; 5. psoriasis; 6 gonorrhea; 7 herpes zoster; 8. osteomyelitis and myelitis; 9 erysipelas; 10. nascsinusitis and frontal sinustits; 11. viral cold and viral ophthalmia; 12. eczema; and 13. carbuncle and cellulitis.

The invention provides a compound for use in treating multiple sclerosis wherein the compound is a 3, 11b-cis-dihydrotetrabenazine of the formula (Ia): or a pharmaceutically acceptable salt thereof.

The invention relates to a medicine composition and a preparation method thereof. The medicine composition comprises the following preparation steps: (1) carrying out reflux extraction on pyrola, drynaria rhizome, caulis spatholobi and semen raphani by using ethyl acetate; (2) mixing solid residues in the step (1) and prepared rehmannia root, and extracting by using 50%-80% alcohol; (3) boiling solid residues in the step (2), and extracting; (4) mixing herba epimedii and herba cistanche, adding calcium carbonate powder, boiling and extracting; (5) combining extracting solution concentrate in each step so as to obtain medicine components, and adding auxiliary materials to the medicine components so as to prepare a preparation as needed. The medicine composition obtained by using the medicine preparation method can be used for treating hypertrophic myelitis, cervical spondylosis, calcaneal spur, hypertrophic arthritis and kashin-beck disease and also provides possibility for the clinical treatment of osteoporosis.

The invention relates to a novel anti-drug resistance antibiotic. In hospitals, more than 70 percent of bacteria causing the infection of patients have drug resistance on at least more than one common antibiotic; the continuous spread of bacterial drug resistance is due to the evolution of the bacteria, however, the abuse of the antibiotic also makes the bacterial drug resistance stronger and stronger; the treatment failure of cephalomeningitis, encephalitis, myelitis, abscess, mammitis and prostatitis are mainly due to the fact that the antibiotic can not be in effective contact with pathogenic bacteria at the infected parts; the antibiotic can not penetrate through a blood brain barrier, a blood milk barrier and other biological barriers; most of antibiotics can be metabolized or inactivated very soon in various routes of administration; when the antibiotic is orally taken, the first-pass effects of the gastrointestinal tracts and the liver can break the chemical structure of the antibiotic, and thereby, most of antibiotic is inactivated; antibiotic injection can bring pains, and for some long-term patients, a long-term place with higher cost needs to be prepared to realize injection; and moreover, blood and the liver can make most of antibiotic inactivated before the antibiotic reaches the action site. The invention provides the novel antibiotic capable of taking effect by using a transdermal administration mode, can avoid the drug inactivation caused by the first-pass effects of the gastrointestinal digestive tracts and the liver and makes the local drug concentration at the infected parts reach the most proper level; meanwhile, the whole body administration is avoided; and since the antibiotic can penetrate through the blood milk barrier and the blood brain barrier, the meningitis, the mammitis, the prostatitis and other infections can be well treated.

The invention discloses a traditional Chinese medicine for treating acute myelitis. The traditional Chinese medicine is prepared from, by weight, 25-35 parts of radix rhapontici, 15-25 parts of cortex albiziae, 20-30 parts of radix ranunculi ternate, 20-30 parts of Sichuan lovage rhizome, 5-10 parts of leech, 10-20 parts of antler and 5-10 parts of licorice root. The pure traditional Chinese medicine is scientific and reasonable in formula, easy to prepare, free of toxic or side effect, short in treatment course, capable of taking effect quickly, and capable of clearing away heat and toxic materials, invigorating the circulation of blood, soothing the nerves, relieving swelling, removing stasis and promoting menstruation and relaxing muscles and tendons. The therapeutic principle of the traditional Chinese medicine is different from that of acute myelitis treatment methods in the prior art.

The invention discloses a 125I particle-containing kit and application thereof. The kit comprises 125I particles, bone cement polymethyl methacrylate and a contrast agent. A Banna minipig test animal model implanted by percutaneous vertebroplasty is established. By the kit, a relationship between irradiation dose and time of radiation myelitis caused by short-distance irradiation of the 125I particles is discussed. By the kit, spinal metastatic tumor patients are treated and researched; and after implantation by the percutaneous vertebroplasty, curative effect is improved and postoperative complications are reduced compared with those by the pure percutaneous vertebroplasty.

The invention discloses a pharmaceutical composition and application thereof in treating acute myelitis. The pharmaceutical composition is prepared from, by weight, 14-16 parts of notoginsenoside R1, 5-6 parts of naringin, 9-11 parts of salicin and 1-2 parts of alpha-pinene, when the raw materials are matched, the pharmaceutical composition has an excellent treatment effect on acute myelitis.